









Markets
/
Stocks
/
nasdaq-iart
/

Integra Lifesciences Holdings Corp

IART

15.380USD

+0.580+3.92%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.20BMarket Cap

LossP/E TTM



Integra Lifesciences Holdings Corp

15.380

+0.580+3.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

89 / 207

Overall Ranking

237 / 4723

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Hold

Current Rating

16.429

Target Price

+10.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 6.94M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -2.26, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 89.38M shares, decreasing 17.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.50M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.13, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 415.61M, representing a year-over-year decrease of 0.61%, while its net profit experienced a year-over-year decrease of 3803.18%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

5.29

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.23

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.23

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.30

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -2.26, which is -4.26% below the recent high of -2.17 and -1428.95% above the recent low of -34.60.

Score

Industry at a Glance

Previous score

2.00

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Integra Lifesciences Holdings Corp is 13.00, with a high of 30.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Hold

Current Rating

16.429

Target Price

+11.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Integra Lifesciences Holdings Corp

IART

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.53, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 16.17 and the support level at 13.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.77

Change

-0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.274

Neutral

RSI(14)

51.875

Neutral

STOCH(KDJ)(9,3,3)

23.249

Sell

ATR(14)

0.618

High Vlolatility

CCI(14)

-35.003

Neutral

Williams %R

75.510

Sell

TRIX(12,20)

0.532

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

15.046

Buy

MA10

15.337

Buy

MA20

15.017

Buy

MA50

13.691

Buy

MA100

13.484

Buy

MA200

17.998

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 114.72%, representing a quarter-over-quarter increase of 2.46%. The largest institutional shareholder is The Vanguard, holding a total of 7.50M shares, representing 9.63% of shares outstanding, with 1.39% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

9.75M

-3.38%

TRU ST Partnership, L.P.

8.52M

The Vanguard Group, Inc.

Star Investors

7.47M

-0.88%

Rubric Capital Management LP

4.64M

+77.35%

Fuller & Thaler Asset Management Inc.

3.92M

-0.25%

Invesco Advisers, Inc.

3.13M

+77.42%

Dimensional Fund Advisors, L.P.

2.58M

+8.95%

State Street Global Advisors (US)

2.75M

-3.70%

Boston Management and Research

2.74M

Paradigm Capital Management, Inc.

1.39M

-3.21%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.18, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.